UK QPPV Requirements Knowledge Assessment

They replace the need for a formal QPPV appointment letter They demonstrate that the QPPV was actually available and involved when urgent decisions were required They prove that every safety report was medically confirmed by the QPPV They are used primarily to calculate the company's marketing expenditure

Number of sales representatives hired Timeliness of expedited reporting and case-processing turnaround times Number of products in the commercial pipeline Total number of external marketing meetings

Allow commercial affairs to implement the change without safety or regulatory review Coordinate safety assessment and risk-minimisation proposals with medical and regulatory functions, followed by appropriate implementation and communication Wait until the next routine annual PSMF review before considering action Delete the signal record once the issue has been escalated

A statement from the responsible manager that the action is complete Documented implementation, effectiveness verification and supporting records showing the underlying issue was addressed A new inspection date with no intervening records Removal of the finding from the inspection history file

To make the PSMF longer regardless of whether the links remain functional To allow inspectors and internal users to trace system descriptions to current supporting evidence To eliminate the need for document version control To ensure that underlying records can be replaced by summaries

To allow senior management to replace the QPPV's scientific assessments To demonstrate active oversight, support escalation and enable informed resourcing and compliance decisions To ensure that all PV decisions are made by the commercial department To avoid maintaining detailed operational records

No documentation is needed because signal validation is a technical task The delegation should be written, time-limited, competency-supported and subject to oversight and review The delegate should assume all QPPV accountability during the six-month period The delegation should be permanent so that the process does not need to be revisited

Personally deciding that every statistical finding is a confirmed safety signal Overseeing signal detection, validation, prioritisation, assessment and documented outcomes Restricting signal review to spontaneous reports from the UK only Transferring all signal decisions to commercial management

To define annual sales targets during business disruption To preserve continuity of QPPV and key PV functions during absence, illness, cyber incidents or other disruptions To replace all routine pharmacovigilance procedures To permit suspension of urgent safety reporting during an incident

Remove all non-UK information from the global PSMF without retaining cross-references Add a distinct UK annex or chapter summarising UK-specific arrangements and allowing prompt retrieval of supporting evidence Rely on the QPPV's verbal explanation during an inspection Create a separate commercial brochure listing only UK products